Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities

Abstract Nucleic acid‐based therapeutics that regulate gene expression have been developed towards clinical use at a steady pace for several decades, but in recent years the field has been accelerating. To date, there are 11 marketed products based on antisense oligonucleotides, aptamers and small i...

Full description

Bibliographic Details
Main Authors:	Suzan M Hammond, Annemieke Aartsma‐Rus, Sandra Alves, Sven E Borgos, Ronald A M Buijsen, Rob W J Collin, Giuseppina Covello, Michela A Denti, Lourdes R Desviat, Lucía Echevarría, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T Goyenvalle, Magdalena Guzowska, Irina Holodnuka, David R Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke Van Roon‐Mom, Virginia Arechavala‐Gomeza
Format:	Article
Language:	English
Published:	Springer Nature 2021-04-01
Series:	EMBO Molecular Medicine
Subjects:	delivery oligonucleotides preclinical models RNA therapeutics safety
Online Access:	https://doi.org/10.15252/emmm.202013243

Similar Items

Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
by: Hammond, SM, et al.
Published: (2021)

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
by: Marlen C. Lauffer, et al.
Published: (2024-01-01)

Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice
by: Lodewijk J.A. Toonen, et al.
Published: (2017-09-01)

Delivery is key: lessons learnt from developing splice-switching antisense therapies
by: Godfrey, C, et al.
Published: (2017)

Splicing modulation therapy in the treatment of genetic diseases
by: Arechavala-Gomeza V, et al.
Published: (2014-12-01)

Antisense oligonucleotide-mediated disruption of HTT caspase-6 cleavage site ameliorates the phenotype of YAC128 Huntington disease mice
by: Elsa C. Kuijper, et al.
Published: (2024-01-01)

Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain
by: Ioannis eZalachoras, et al.
Published: (2011-07-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy.
by: Goyenvalle, A, et al.
Published: (2011)

Therapeutic Strategies for Spinocerebellar Ataxia Type 1
by: Laurie M. C. Kerkhof, et al.
Published: (2023-05-01)

Challenges to oligonucleotides-based therapeutics for Duchenne muscular dystrophy
by: Goyenvalle Aurélie, et al.
Published: (2011-02-01)

Measuring DNA hybridization using fluorescent DNA-stabilized silver clusters to investigate mismatch effects on therapeutic oligonucleotides
by: Donny de Bruin, et al.
Published: (2018-04-01)

A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures.
by: Monika Hiller, et al.
Published: (2018-01-01)

Correction: Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B.
by: Simon Krooss, et al.
Published: (2021-01-01)

The MID1 Protein: A Promising Therapeutic Target in Huntington’s Disease
by: Annika Heinz, et al.
Published: (2021-10-01)

DMD antisense oligonucleotide mediated exon skipping efficiency correlates with flanking intron retention time and target position within the exon
by: Remko Goossens, et al.
Published: (2023-12-01)

Special Issue “Genetic Advances in Neuromuscular Disorders: From Gene Identification to Gene Therapy”
by: Virginia Arechavala-Gomeza, et al.
Published: (2021-02-01)

Antisense-mediated isoform switching of steroid receptor coactivator-1 in the central nucleus of the amygdala of the mouse brain
by: Zalachoras Ioannis, et al.
Published: (2013-01-01)

Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model
by: Karima Relizani, et al.
Published: (2017-09-01)

Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: Removal of the CAG containing exon
by: Melvin M. Evers, et al.
Published: (2013-10-01)

Amyloid beta accumulations and enhanced neuronal differentiation in cerebral organoids of Dutch-type cerebral amyloid angiopathy patients
by: Elena Daoutsali, et al.
Published: (2023-01-01)

Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology
by: Alejandro Fulgencio-Covián, et al.
Published: (2020-12-01)

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
by: Jeroen Bremer, et al.
Published: (2016-01-01)

A dystrophic Duchenne mouse model for testing human antisense oligonucleotides.
by: Marcel Veltrop, et al.
Published: (2018-01-01)

Good news for the mdx mouse community: Improved dystrophin restoration after skipping mouse dystrophin exon 23
by: Annemieke Aartsma-Rus
Published: (2022-12-01)

Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
by: Valérie Robin, et al.
Published: (2017-06-01)

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice
by: Flavien Bizot, et al.
Published: (2022-12-01)

Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy
by: Maaike van Putten, et al.
Published: (2014-01-01)

Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B.
by: Simon Krooss, et al.
Published: (2020-04-01)

Antisense Oligonucleotide-Based Rescue of Aberrant Splicing Defects Caused by 15 Pathogenic Variants in <i>ABCA4</i>
by: Tomasz Z. Tomkiewicz, et al.
Published: (2021-04-01)

Novel Orthogonally Hydrocarbon-Modified Cell-Penetrating Peptide Nanoparticles Mediate Efficient Delivery of Splice-Switching Antisense Oligonucleotides In Vitro and In Vivo
by: Safa Bazaz, et al.
Published: (2021-08-01)

A Sensitive Assay System To Test Antisense Oligonucleotides for Splice Suppression Therapy in the Mouse Liver
by: Lorena Gallego-Villar, et al.
Published: (2014-01-01)

Generation of 3 spinocerebellar ataxia type 1 (SCA1) patient-derived induced pluripotent stem cell lines LUMCi002-A, B, and C and 2 unaffected sibling control induced pluripotent stem cell lines LUMCi003-A and B
by: Ronald A.M. Buijsen, et al.
Published: (2018-05-01)

Increased sensitivity of next generation sequencing-based expression profiling after globin reduction in human blood RNA
by: Mastrokolias Anastasios, et al.
Published: (2012-01-01)

Antisense-oligonucleotide mediated exon skipping in activin-receptor-like kinase 2: inhibiting the receptor that is overactive in fibrodysplasia ossificans progressiva.
by: Songting Shi, et al.
Published: (2013-01-01)

VALIDATION OF THERAPEUTIC SIRNAS IN HIPSC-DERIVED FTDP-17 NEURONAL MODEL OF TAUOPATHY
by: Ilaria Brentari, et al.
Published: (2023-10-01)

The use of genetically humanized animal models for personalized medicine approaches
by: Annemieke Aartsma-Rus, et al.
Published: (2020-02-01)

Co-expression patterns of microglia markers Iba1, TMEM119 and P2RY12 in Alzheimer's disease
by: Boyd Kenkhuis, et al.
Published: (2022-06-01)

Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides.
by: Hassane, F, et al.
Published: (2011)

Navigating public health clinical placements for rural online RN-BSN students
by: Jill C. Borgos
Published: (2021-05-01)

HCS-Splice: A High-Content Screening Method to Advance the Discovery of RNA Splicing-Modulating Therapeutics
by: Giuseppina Covello, et al.
Published: (2023-07-01)